DOCSLIB.ORG

Cerebral Amyloidosis, Amyloid Angiopathy, and Their Relationship to Stroke and Dementia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cerebral Amyloidosis, Amyloid Angiopathy, and Their Relationship to Stroke and Dementia 65 Cerebral amyloidosis, amyloid angiopathy, and their relationship to stroke and dementia ∗ Jorge Ghiso and Blas Frangione β-pleated sheet structure, the conformation responsi- Department of Pathology, New York University School ble for their physicochemical properties and tinctoreal of Medicine, New York, NY, USA characteristics. So far, 20 different proteins have been identified as subunits of amyloid fibrils [56,57,60 (for review and nomenclature)]. Although collectively they Cerebral amyloid angiopathy (CAA) is the common term are products of normal genes, several amyloid precur- used to define the deposition of amyloid in the walls of sors contain abnormal amino acid substitutions that can medium- and small-size leptomeningeal and cortical arteries, arterioles and, less frequently, capillaries and veins. CAA impose an unusual potential for self-aggregation. In- is an important cause of cerebral hemorrhages although it creased levels of amyloid precursors, either in the cir- may also lead to ischemic infarction and dementia. It is a culation or locally at sites of deposition, are usually the feature commonly associated with normal aging, Alzheimer result of overexpression, defective clearance, or both. disease (AD), Down syndrome (DS), and Sporadic Cerebral Of all the amyloid proteins identified, less than half are Amyloid Angiopathy. Familial conditions in which amyloid known to cause amyloid deposition in the central ner- is chiefly deposited as CAA include hereditary cerebral hem- vous system (CNS), which in turn results in cognitive orrhage with amyloidosis of Icelandic type (HCHWA-I), fa- decline, dementia, stroke, cerebellar and extrapyrami- milial CAA related to Aβ variants, including hereditary cere- dal signs, or a combination of them. bral hemorrhage with amyloidosis of Dutch origin (HCHWA- D), the transthyretin-related meningocerebrovascular amyloi- dosis of Hungarian and Ohio kindreds, the gelsolin-related 2. Aβ – related cerebral amyloidosis spinal and cerebral amyloid angiopathy, familial PrP-CAA, and the recently described chromosome 13 familial dementia in British and Danish kindreds. This review focuses on the Alzheimer’s disease (AD) is an age-dependent neu- various molecules and genetic variants that target the cere- rodegenerative disorder that causes a chronically pro- bral vessel walls producing clinical features related to stroke gressive decline in cognitive functions. The brains of and/or dementia, and discusses the potential role of amyloid patients suffering from AD are characterized by the in the mechanism of neurodegeneration. extracellular deposition of amyloid Aβ (Aβ) protein in plaques and cerebral blood vessels, the presence of intraneuronal neurofibrillary tangles (NFT) and reac- 1. Introduction tive gliosis, and the loss of presynaptic terminals and neuronal subpopulations in well defined brain areas. Amyloidosis is a disorder of protein conformation At autopsy, senile plaques and NFT chiefly define the leading to aggregation and fibrillization. A diverse disease whereas other pathological features are often group of proteins normally present in body fluids as ignored or regarded as coincidental findings. It is now soluble precursors can self-assemble into amyloid fib- becoming clear that a large majority of the patients rils and produce insoluble deposits in different tissues diagnosed with AD when examined at autopsy bear which may lead to cell damage, organ dysfunction and stroke-like lesions or infarctions, ranging from CAA, death. These fibrils, composed of low molecular weight degenerative microangiopathy compromising both the mass peptides (∼ 4 to 30 kDa), adopt a predominant endothelium and smooth muscle cells,cerebral infarcts, microinfarction, white matter changes related to small ∗ vessel disease and even hemorrhages [20,22,58]. Al- Correspondence to: Jorge Ghiso, Ph.D., Department of Pathol- though it is accepted that the presence of cerebrovas- ogy, New York University School of Medicine, 550 First Avenue, room TH-432, New York, NY 10016, USA. Tel.: +1 212 263 5775; cular disease or strokes may cause rapid cognitive de- Fax: +1 212 263 6751. cline and worsen the outcome in AD, it remains debat- Journal of Alzheimer’s Disease 3 (2001) 65–73 ISSN 1387-2877 / $8.00 2001, IOS Press. All rights reserved 66 J. Ghiso and B. Frangione / Cerebral amyloidosis, amyloid angiopathy, and their relationship to stroke and dementia able whether the vascular lesions are coincidental or sive amyloid deposition in the walls of leptomeningeal causal to the pathological processes. In sporadic AD, and cortical arteries and arterioles as well as in vessels wild type Aβ species, 39 to 43 residues in length, are in the brainstem and cerebellum. In addition to the the main constituents of the parenchymal and vascular vascular involvement, there is a moderate number of amyloid lesions and the inheritance of the apolipopro- parenchymal amyloid deposits resembling the diffuse tein E (apoE, chromosome 19) 4 allele is a prevailing plaques seen in Alzheimer disease. Dense plaque cores risk factor [31,40,49,61]. and neurofibrillary tangles are absent; cortical and hip- Mutations in the amyloid precursor protein (AβPP) pocampal neurons outside the infarcts appear to be well on chromosome 21 or presenilins (PS) 1 (chromo- preserved. Cerebral and cerebellar white matter show some 14) and 2 (chromosome 1) genes have been linked varying degrees of edema and myelin loss. The amy- to autosomal dominant forms of familial AD (FAD) loid subunit in HCHWA-D is homologous to Aβ; amy- (reviewed in [48]). As indicated in Fig. 1, multiple loid deposits are composed of a mixture of wild-type mutation sites either within or immediately outside the Aβ peptide and the Aβ-Q22 variant [41,54]. A single Aβ segment have been identified in the AβPP gene. nucleotide change (G for C) at codon 693 of AβPP [26] Surprisingly, AβPP mutations found outside the Aβ results in a single amino acid substitution (glutamine peptide are mainly associated with dementia whereas for glutamic acid) at position 22 of the Aβ peptide. those found inside the Aβ sequence result is stroke This was the first of a large series of mutations in the as the main clinical phenotype. These genetic vari- AβPP gene described in several kindreds with early on- ants are concentrated in the middle of the Aβ sequence set familial Alzheimer disease [48] (Fig. 1). Although (positions 21–22, corresponding to codons 692–693 the mechanism of fibril formation is not known, in vitro of AβPP) and are invariably associated with extensive studies [3,5,62] have shown that the Aβ-Q22 variant cerebrovascular pathology. The Flemish mutation A to forms fibrils at a more accelerated rate than wild-type G at codon 692), is the only variant so far described at Aβ. This increased amyloidogenic tendency is prob- position 21, resulting in an Ala to Gly substitution and ably due to a higher content of β-pleated sheet struc- a clinical phenotype of presenile dementia and cerebral ture and a conformational change in the middle part hemorrhage [19]. At position 22 of Aβ, three variants of the molecule induced by the disappearance of the have been described: i) the Arctic mutation (A to G negatively charged Glu side-chain in the mutant pep- at codon 693, resulting in the replacement of Glu for tide [9,45]. The presence of both allele products in the Gly), presenting as an early onset AD with prominent amyloid deposits suggest that the mutant peptide may vascular symptomathology [23], ii) the Dutch mutation induce a conformational change in the structure of the (G to C at codon 693, with the subsequent replacement normal Aβ peptide. Treatments to inhibit amyloidoge- of Glu for Gln), showing a phenotype predominantly nesis have been proposed [44,46]. associated to cerebral hemorrhage (see below) [26],and iii) the Italian mutation (G to A at codon 693, bearing Lys for Glu), presenting as a presenile dementia with 3. Cystatin C – related cerebral amyloid cerebral hemorrhage [51]. The deposition of these vas- angiopathy culotropic mutants in the cerebral vessel walls suggest alteration of the clearance-uptake mechanisms at the Hereditary cerebral hemorrhage with amyloidosis, blood-brain barrier. Icelandic type (HCHWA-I) is an autosomal dominant Of interest is the first mutation described in the disorder characterized by massive amyloid deposition AβPP gene linked to hereditary cerebral hemorrhage within small arteries and arterioles of leptomeninges, with amyloidosis, Dutch type (HCHWA-D), an auto- cerebral cortex, basal ganglia, brainstem and cerebel- somal dominant disease clinically defined by recurrent lum [16]. Although brain involvement is the main clini- strokes, vascular dementia and fatal cerebral bleeding copathological feature, silent amyloid deposits are also in the fifth to sixth decades of life [30]. Pedigrees present in peripheral tissues such as skin, lymph nodes, from the villages of Katwijk and Scheveningen have spleen, salivary glands, and seminal vesicles [2]. been described in The Netherlands [29]. Around two- Including information on progenitors born up to 200 thirds of the patients will die as a result of the first years ago, seven pedigrees have been described in small acute cerebral hemorrhage, while the rest will have sev- rural communities of West Iceland [21]. The main clin- eral minor stroke episodes leading to cognitive decline ical hallmark of the disease is cerebral hemorrhage with and dementia [18,59]. Histologically, there is a mas- fatal outcome in the third to fourth decade of life in J. Ghiso and B. Frangione / Cerebral amyloidosis, amyloid angiopathy, and their relationship to stroke and dementia 67 Stroke Dementia Dementia T H M V R D & Stroke F S 670 E 700 * *** 717 723 A G 680 ... E V KM D Y 28 K G A I I G L M V G G V V I A T V I V I T L V M L S 1 E N 40 42 I V G S .. E H G . H V Q D K E L 690 A V F F D N L V T I F G P QKG Dementia Schizophrenia Dementia Dementia Stroke Fig.
Load more

Recommended publications
  • The Study of the Formation of Oligomers and Amyloid Plaques from Amylin by Capillary Electrophoresis and Fluorescent Microchip E
    University of Arkansas, Fayetteville ScholarWorks@UARK Biological and Agricultural Engineering Biological and Agricultural Engineering Undergraduate Honors Theses 5-2015 The tuds y of the formation of oligomers and amyloid plaques from Amylin by capillary electrophoresis and fluorescent microchip electrophoresis Shane Weindel University of Arkansas, Fayetteville Follow this and additional works at: http://scholarworks.uark.edu/baeguht Part of the Engineering Commons Recommended Citation Weindel, Shane, "The tudys of the formation of oligomers and amyloid plaques from Amylin by capillary electrophoresis and fluorescent microchip electrophoresis" (2015). Biological and Agricultural Engineering Undergraduate Honors Theses. 25. http://scholarworks.uark.edu/baeguht/25 This Thesis is brought to you for free and open access by the Biological and Agricultural Engineering at ScholarWorks@UARK. It has been accepted for inclusion in Biological and Agricultural Engineering Undergraduate Honors Theses by an authorized administrator of ScholarWorks@UARK. For more information, please contact [email protected], [email protected]. The Study of the Formation of Oligomers and Amyloid Plaques from Amylin by Capillary Electrophoresis and Fluorescent Microchip Electrophoresis Shane Weindel, Biological Engineering Undergraduate Christa Hestekin, Chemical Engineering Assistant Professor Department of Biological & Agricultural Engineering 203 Engineering Hall 1 University of Arkansas Abstract Amylin, a pancreatic β-cell hormone, was the focus of this research project. This hormone is co-localized and co-secreted with insulin in response to nutrient stimuli. The hormone inhibits food intake, gastric emptying and glucagon secretion. Insulin and amylin appear to complement each other in the control of plasma glucose levels. Human amylin has a propensity to self-aggregate and to form insoluble bodies.
    [Show full text]
  • Familial Mediterranean Fever: Effects of Genotype and Ethnicity on Inflammatory Attacks and Amyloidosis
    Familial Mediterranean Fever: Effects of Genotype and Ethnicity on Inflammatory Attacks and Amyloidosis Aviva Mimouni, MD*; Nurit Magal, PhD*; Nava Stoffman, MD*; Tamy Shohat, MD*; Ara Minasian, MD‡; Michael Krasnov, MD*; Gabrielle J. Halpern, MRCPsych*; Jerome I. Rotter, MD§; Nathan Fischel-Ghodsian, MD§; Yehuda L. Danon, MDʈ; and Mordechai Shohat, MD* ABSTRACT. Objective. The gene causing familial factors other than genotype, such as environment or genes Mediterranean fever (FMF)—an autosomal recessive dis- other than MEFV, play a role in the determination of the ease characterized by recurrent short episodes of fever severity of the inflammatory attacks in FMF. Pediatrics associated most commonly with peritonitis, pleuritis, 2000;105(5). URL: http://www.pediatrics.org/cgi/content/ and arthritis—has recently been found and several mu- full/105/5/e70; amyloidosis, specific mutation, phenotype-ge- tations identified. The most severe complication of the notype correlation, ethnicity. disease is amyloidosis, which can lead to renal failure. The aim of this study was to investigate the role of genetic versus nongenetic factors on the phenotype as ABBREVIATIONS. FMF, familial Mediterranean fever; MEFV, well as on the development of amyloidosis in FMF in a Mediterranean fever (the FMF gene); PCR, polymerase chain re- large and heterogeneous group of patients. action; CI, confidence interval. Methodology. We studied 382 patients from 4 ethnic origins living in different environments: North African amilial Mediterranean fever (FMF) is an auto- Jews, other Jews, Turks, Armenians living in the United somal recessive disease affecting primarily non- States, and Armenians from Yerevan, Armenia. Informa- tion regarding amyloidosis was available for 371 pa- Ashkenazi Jews, Armenians, Turks, and Ar- F1 tients.
    [Show full text]
  • Beta Amyloid Imaging with Positron Emission Tomography For
    Corporate Medical Policy Beta Amyloid Imaging With Positron Emission Tomography for Alzheimer’s Disease File Name: beta_amyloid_imaging_with_positron_emission_tomography_for_alzheimers_disease Origination: 10/2014 Last CAP Review: 5/2021 Next CAP Review: 5/2022 Last Review: 5/2021 Description of Procedure or Service Three radioactive tracers (florbetapir F18, flutemetamol F18, florbetaben F18) that bind to beta amyloid and can be detected in vivo with positron emission tomography (PET) have been developed. This technology is being evaluated to detect beta amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer disease (AD) and/or other causes of cognitive decline. Background The diagnosis of AD is divided into 3 categories: possible, probable, and definite AD. A diagnosis of definite AD requires postmortem confirmation of AD pathology, including the presence of extracellular beta amyloid plaques and intraneuronal neurofibrillary tangles in the cerebral cortex. There can be a range of beta amyloid plaques and neurofibrillary tanges on histopathology that support a low, intermediate or high probability of AD. Probable AD dementia is diagnosed clinically when the patient meets core clinical criteria for dementia and has a typical clinical course for AD. A typical clinical course is defined as an insidious onset, with the initial and most prominent cognitive deficits being either amnestic or nonamnestic, e.g., language, visuospatial, or executive function deficits, and a history of progressively worsening cognition over time. A diagnosis of possible AD dementia is made when the patient meets the core clinical criteria for AD dementia but has an atypical course or an etiologically mixed presentation. Mild cognitive impairment (MCI) may be diagnosed when there is a change in cognition, but impairment is insufficient for the diagnosis of dementia.
    [Show full text]
  • A Guide to Transthyretin Amyloidosis
    A Guide to Transthyretin Amyloidosis Authored by Teresa Coelho, Bo-Goran Ericzon, Rodney Falk, Donna Grogan, Shu-ichi Ikeda, Mathew Maurer, Violaine Plante-Bordeneuve, Ole Suhr, Pedro Trigo 2016 Edition Edited by Merrill Benson, Mathew Maurer What is amyloidosis? Amyloidosis is a systemic disorder characterized by extra cellular deposition of a protein-derived material, known as amyloid, in multiple organs. Amyloidosis occurs when native or mutant poly- peptides misfold and aggregate as fibrils. The amyloid deposits cause local damage to the cells around which they are deposited leading to a variety of clinical symptoms. There are at least 23 different proteins associated with the amyloidoses. The most well-known type of amyloidosis is associated with a hematological disorder, in which amyloid fibrils are derived from monoclonal immunoglobulin light-chains (AL amyloidosis). This is associated with a clonal plasma cell disorder, closely related to and not uncommonly co-existing with multiple myeloma. Chronic inflammatory conditions such as rheumatoid arthritis or chronic infections such as bronchiectasis are associated with chronically elevated levels of the inflammatory protein, serum amyloid A, which may misfold and cause AA amyloidosis. The hereditary forms of amyloidosis are autosomal dominant diseases characterized by deposition of variant proteins, in dis- tinctive tissues. The most common hereditary form is transthyretin amyloidosis (ATTR) caused by the misfolding of protein monomers derived from the tetrameric protein transthyretin (TTR). Mutations in the gene for TTR frequently re- sult in instability of TTR and subsequent fibril formation. Closely related is wild-type TTR in which the native TTR protein, particu- larly in the elderly, can destabilize and re-aggregate causing non- familial cases of TTR amyloidosis.
    [Show full text]
  • Once AL Amyloidosis: Not Always AL Amyloidosis
    Amyloid The Journal of Protein Folding Disorders ISSN: 1350-6129 (Print) 1744-2818 (Online) Journal homepage: http://www.tandfonline.com/loi/iamy20 Once AL amyloidosis: not always AL amyloidosis Tulip Jhaveri, Shayna Sarosiek, Frederick L. Ruberg, Omar Siddiqi, John L. Berk & Vaishali Sanchorawala To cite this article: Tulip Jhaveri, Shayna Sarosiek, Frederick L. Ruberg, Omar Siddiqi, John L. Berk & Vaishali Sanchorawala (2018): Once AL amyloidosis: not always AL amyloidosis, Amyloid, DOI: 10.1080/13506129.2018.1449104 To link to this article: https://doi.org/10.1080/13506129.2018.1449104 Published online: 08 Mar 2018. Submit your article to this journal View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=iamy20 AMYLOID, 2018 https://doi.org/10.1080/13506129.2018.1449104 LETTER TO THE EDITOR Once AL amyloidosis: not always AL amyloidosis Amyloid cardiomyopathy could be related to AL amyloidosis, He continued with haematologic complete response at this wild-type transthyretin amyloidosis (ATTRwt) or hereditary time without recurrence of lymphoma. In view of continued amyloidosis (ATTRm). It is crucial to distinguish and accur- hematologic CR and new cardiomyopathy, an endomyocardial ately type the precursor amyloidogenic protein in order to biopsy (age 76 years) revealed amyloid deposition by Congo offer appropriate treatment, prognosis and genetic counsel- red staining. Microdissection and liquid chromatography ing. Treatment for AL amyloidosis is directed towards the with laser capture tandem mass spectrometry identified plasma cell dyscrasia, whereas treatment for transthyretin transthyretin protein as the precursor amyloid protein. Serum amyloidosis is directed towards stabilization of misfolded isoelectric focusing and genetic testing demonstrated normal TTR [1] or reduction in production of mutant TTR [2,3].
    [Show full text]
  • Expert Consensus Recommendations to Improve Diagnosis of ATTR Amyloidosis with Polyneuropathy
    Journal of Neurology https://doi.org/10.1007/s00415-019-09688-0 REVIEW Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy David Adams1 · Yukio Ando2 · João Melo Beirão3 · Teresa Coelho4 · Morie A. Gertz5 · Julian D. Gillmore6 · Philip N. Hawkins6 · Isabelle Lousada7 · Ole B. Suhr8 · Giampaolo Merlini9,10 Received: 10 December 2019 / Revised: 20 December 2019 / Accepted: 23 December 2019 © The Author(s) 2020 Abstract Amyloid transthyretin (ATTR) amyloidosis with polyneuropathy (PN) is a progressive, debilitating, systemic disease wherein transthyretin protein misfolds to form amyloid, which is deposited in the endoneurium. ATTR amyloidosis with PN is the most serious hereditary polyneuropathy of adult onset. It arises from a hereditary mutation in the TTR gene and may involve the heart as well as other organs. It is critical to identify and diagnose the disease earlier because treatments are available to help slow the progression of neuropathy. Early diagnosis is complicated, however, because presentation may vary and family history is not always known. Symptoms may be mistakenly attributed to other diseases such as chronic infammatory demyelinating polyradiculoneuropathy (CIDP), idiopathic axonal polyneuropathy, lumbar spinal stenosis, and, more rarely, diabetic neuropathy and AL amyloidosis. In endemic countries (e.g., Portugal, Japan, Sweden, Brazil), ATTR amyloidosis with PN should be suspected in any patient who has length-dependent small-fber PN with autonomic dysfunction and a family history of ATTR amyloidosis, unexplained weight loss, heart rhythm disorders, vitreous opacities, or renal abnormali- ties. In nonendemic countries, the disease may present as idiopathic rapidly progressive sensory motor axonal neuropathy or atypical CIDP with any of the above symptoms or with bilateral carpal tunnel syndrome, gait disorders, or cardiac hypertro- phy.
    [Show full text]
  • BRI2 (Itm2b) Inhibits A␤ Deposition in Vivo
    6030 • The Journal of Neuroscience, June 4, 2008 • 28(23):6030–6036 Neurobiology of Disease BRI2 (ITM2b) Inhibits A␤ Deposition In Vivo Jungsu Kim,1 Victor M. Miller,1 Yona Levites,1 Karen Jansen West,1 Craig W. Zwizinski,1 Brenda D. Moore,1 Fredrick J. Troendle,1 Maralyssa Bann,1 Christophe Verbeeck,1 Robert W. Price,1 Lisa Smithson,1 Leilani Sonoda,1 Kayleigh Wagg,1 Vijayaraghavan Rangachari,1 Fanggeng Zou,1 Steven G. Younkin,1 Neill Graff-Radford,2 Dennis Dickson,1 Terrone Rosenberry,1 and Todd E. Golde1 Departments of 1Neuroscience and 2Neurology, Mayo Clinic College of Medicine, Mayo Clinic Jacksonville, Jacksonville, Florida 32224 AnalysesofthebiologiceffectsofmutationsintheBRI2(ITM2b)andtheamyloid␤precursorprotein(APP)genessupportthehypothesis that cerebral accumulation of amyloidogenic peptides in familial British and familial Danish dementias and Alzheimer’s disease (AD) is associatedwithneurodegeneration.WehaveusedsomaticbraintransgenictechnologytoexpresstheBRI2andBRI2-A␤1–40transgenes in APP mouse models. Expression of BRI2-A␤1–40 mimics the suppressive effect previously observed using conventional transgenic methods, further validating the somatic brain transgenic methodology. Unexpectedly, we also find that expression of wild-type human BRI2 reduces cerebral A␤ deposition in an AD mouse model. Additional data indicate that the 23 aa peptide, Bri23, released from BRI2 by normal processing, is present in human CSF, inhibits A␤ aggregation in vitro and mediates its anti-amyloidogenic effect in vivo. These studies demonstrate that BRI2 is a novel mediator of A␤ deposition in vivo. Key words: BRI2; ITM2b; amyloid ␤ protein; Alzheimer’s disease; somatic brain transgenesis; adeno-associated virus Introduction pathological and clinical similarities between FBD, FDD, and Familial British and Danish dementias (FBD and FDD, respec- Alzheimer’s disease (AD).
    [Show full text]
  • Expression of Atrial and Brain Natriuretic Peptides and Their Genes in Hearts of Patients with Cardiac Amyloidosis
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector 754 JACC Vol. 31, No. 4 March 15, 1998:254–65 Expression of Atrial and Brain Natriuretic Peptides and Their Genes in Hearts of Patients With Cardiac Amyloidosis GENZOU TAKEMURA, MD,*† YOSHIKI TAKATSU, MD,* KIYOSHI DOYAMA, MD,‡ HIROSHI ITOH, MD,‡ YOSHIHIKO SAITO, MD,‡ MASATOSHI KOSHIJI, MD,† FUMITAKA ANDO, MD,* TAKAKO FUJIWARA, MD,§ KAZUWA NAKAO, MD,‡ HISAYOSHI FUJIWARA, MD† Hyogo, Gifu and Kyoto, Japan Objectives. We investigated the expression of atrial natriuretic secretory granules in ventricular myoctyes of the patients with peptide (ANP) and brain natriuretic peptide (BNP) and their cardiac amyloidosis, but not in ventricular myocytes from the genes in the hearts of patients with cardiac amyloidosis and those normal control subjects. Double immunocytochemical analysis with isolated atrial amyloidosis. revealed the co-localization of ANP and BNP in the same granules Background. The expression of ANP and BNP is augmented in and that isolated atrial amyloid fibrils were immunoreactive for the ventricles of failing or hypertrophied hearts, or both. The ANP and BNP, whereas ventricular amyloid fibrils were negative expression of ANP and BNP in the ventricles of hearts with for both peptides. Both ANP mRNA and BNP mRNA were cardiac amyloidosis, which is hemodynamically similar to restric- expressed in the ventricles of the patients with cardiac amyloid- tive cardiomyopathy, is not yet known. ANP is the precursor osis but not in the normal ventricles. The autopsy study of four protein of isolated atrial amyloid. patients with cardiac amyloidosis revealed an almost transmural Methods.
    [Show full text]
  • Recognizing TTR-FAP Transthyretin Familial Amyloid Polyneuropathy
    This version is Global RC approved and local adaptation and approval is mandatory before distribution. Countries are responsible for language accuracy. Content to be updated with local information and labeling as required. Recognizing TTR-FAP Transthyretin Familial Amyloid Polyneuropathy About TTR-FAP TTR-FAP is a rare, genetic, TTR-FAP is caused by a mutation in the transthyretin gene, which can result in abnormal and unstable progressive and fatal transthyretin proteins. 2,3 neurodegenerative disease affecting an estimated 10,000 people worldwide.1 TTR-FAP – A Disease of Protein Misfolding Free Tetramer Folded Misfolded Toxic Intermediates Monamer Monamer & Amyloid Fibrils TTR-FAP affects men and women equally. Monamer Aggregation Misfolding Functional TTR Structures TTR Structures Symptoms usually begin to affect Associated with Pathology people in their 30s. These abnormal proteins build up and form toxic This varies with genetics and structures called amyloid fibrils, which may deposit in the peripheral nervous system, leading to a decline in ethnic background.2,3 The life neurologic function, or in other parts of the body, such expectancy for someone who as the heart, digestive system, and kidneys.2,3,4,5,6,7 is diagnosed with TTR-FAP is said to be about 10 years.13 Where is TTR-FAP Most Prevalent? There are clusters of TTR-FAP patients in Portugal, Japan, and Sweden.8 TTR-FAP is also found in countries such as the United States, various countries in Europe (e.g., France, Italy, Spain, Germany, and UK), Brazil, and Taiwan.9 Prevalence of TTR-FAP may vary by country of origin and by the type of TTR gene mutation.10 Symptoms of TTR-FAP Symptoms vary, but often, the feet Later, weakness gets worse in the and legs are affected first—with legs.11 The arms may be affected pain, tingling, numbness, or loss of too, starting at the figertips.11 the ability to feel hot and cold.11 Why Early Diagnosis is Key Although the disease affects people differently, it typically gets worse over time and can progress rapidly.
    [Show full text]
  • Unbiased RNA-Seq-Driven Identification and Validation Of
    Dai et al. BMC Genomics (2021) 22:27 https://doi.org/10.1186/s12864-020-07318-y RESEARCH ARTICLE Open Access Unbiased RNA-Seq-driven identification and validation of reference genes for quantitative RT-PCR analyses of pooled cancer exosomes Yao Dai1, Yumeng Cao1, Jens Köhler2, Aiping Lu1, Shaohua Xu1* and Haiyun Wang1* Abstract Background: Exosomes are extracellular vesicles (EVs) derived from endocytic compartments of eukaryotic cells which contain various biomolecules like mRNAs or miRNAs. Exosomes influence the biologic behaviour and progression of malignancies and are promising candidates as non-invasive diagnostic biomarkers or as targets for therapeutic interventions. Usually, quantitative real-time polymerase chain reaction (qRT-PCR) is used to assess gene expression in cancer exosomes, however, the ideal reference genes for normalization yet remain to be identified. Results: In this study, we performed an unbiased analysis of high-throughput mRNA and miRNA-sequencing data from exosomes of patients with various cancer types and identify candidate reference genes and miRNAs in cancer exosomes. The expression stability of these candidate reference genes was evaluated by the coefficient of variation “CV” and the average expression stability value “M”. We subsequently validated these candidate reference genes in exosomes from an independent cohort of ovarian cancer patients and healthy control individuals by qRT-PCR. Conclusions: Our study identifies OAZ1 and hsa-miR-6835-3p as the most reliable individual reference genes for mRNA and miRNA quantification, respectively. For superior accuracy, we recommend the use of a combination of reference genes - OAZ1/SERF2/MPP1 for mRNA and hsa-miR-6835-3p/hsa-miR-4468-3p for miRNA analyses.
    [Show full text]
  • Cardiac Amyloidosis
    Cardiac Amyloidosis Ronald Witteles, MD Stanford University & Brendan M. Weiss, MD University of Pennsylvania Amyloidosis: What is it? • Amylum – Starch (Latin) • Generic term for many diseases: • Protein misfolds into β-sheets • Forms into 8-10 nm fibrils • Extracellular deposition into amyloid deposits Types of Amyloid – Incomplete List • Systemic: • Light chains (AL) – “Primary ” • Transthyretin (ATTR) – “Senile ” or “Familial ” or “FAC” or “FAP” • Serum amyloid A (AA) – “Secondary ” • Localized – Not to be memorized! • Beta-2 microglobulin (A-β2) – Dialysis (osteoarticular structures) • Apolipoprotein A-1 (AApoA-I) – Age-related (aortic intima, cardiac, neuropathic) • Apolipoprotein A-2 (AApoA-2) – Hereditary (kidney) • Calcitonin (ACal) – Complication of thyroid medullary CA • Islet amyloid polypeptide (AIAPP) – Age-related (seen in DM) • Atrial natriuretic peptide (AANF) – Age-related (atrial amyloidosis) • Prolactin (APro) – Age-related, pituitary tumors • Insulin (AIns) – Insulin-pump use (local effects) • Amyloid precursor protein (ABeta) – Age-related/hereditary (Alzheimers) • Prion protein (APrPsc) – Hereditary/sporadic (spongiform encephalopathies) • Cystatin-C (ACys) – Hereditary (cerebral hemorrhage) • Fibrinogen alpha chain (AFib) – Hereditary (kidney) • Lysozome (ALys) – Hereditary (Diffuse, especially kidney, spares heart) • Medin/Lactadherin – Age-related (medial aortic amyloidosis) • Gelsolin (AGel) – Hereditary (neuropathic, corneal) • Keratin – Cutaneous AL: A Brief Dive into Hematology… Plasma cells: Make antibodies
    [Show full text]
  • Breakthroughs in Antemortem Diagnosis of Neurodegenerative Diseases COMMENTARY Glenn C
    COMMENTARY Breakthroughs in antemortem diagnosis of neurodegenerative diseases COMMENTARY Glenn C. Tellinga,1 The World Health Organization forecasts that within 2 Abnormal cytoplasmic accumulation of a normally sol- decades neurodegenerative disorders will eclipse can- uble and unfolded protein called α-synuclein is the cer to become the foremost cause of death in the de- hallmark of diseases referred to as synucleinopathies. veloped world after cardiovascular disease. Accurate Neuronal deposition of α-synuclein aggregates in Lewy detection of pathological processes goes hand in hand bodies occurs in Parkinson’s disease (PD) and dementia with the goals of treatment and prevention and, in light with Lewy bodies (DLB). Yet another protein—the prion of their protracted but worsening clinical progression, protein (PrP)—is central to a group of interrelated dis- the earlier a diagnosis can be made the better. How- orders commonly referred to as prion diseases. ever, the challenge underlying accurate detection of Since the concept underlying the diagnostic ap- neurodegenerative diseases during their clinical phase proach taken by Metrick et al. (1) derives from studies is that specific biomarkers are not present at high of prions, it is worth reviewing what we have learned enough concentrations for routine detection in acces- about PrP and the applicability of these findings to sible specimens. Consequently, it has only been pos- other proteopathic diseases. The prion disorders are sible to definitively diagnose these conditions by transmissible neurodegenerative diseases affecting examination of brain pathology after death. The paper animals and humans. The most common human form by Metrick et al. (1) in PNAS addresses the issue of is Creutzfeldt–Jakob disease (CJD) which occurs most improved antemortem biomarker detection for a frequently as a sporadic, rapidly progressive condition spectrum of neurological disorders, using assays of older individuals.
    [Show full text]